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Abstract
Kampo formulations used in Japan to treat a wide variety of diseases and to promote health
are composed of mixtures of crude extracts from the roots, bark, leaves, and rhizomes of a
number of herbs. The present study was aimed at identifying the beneficial biological prop-
erties of Daiokanzoto (TJ-84), a Kampo formulation composed of crude extracts of Rhubarb
rhizomes and Glycyrrhiza roots, with a view to using it as a potential treatment for periodon-
tal disease. Daiokanzoto dose-dependently inhibited the expression of major Porphyromo-
nas gingivalis virulence factors involved in host colonization and tissue destruction. More
specifically, Daiokanzoto reduced the expression of the fimA, hagA, rgpA, and rgpB genes,
as determined by quantitative real-time PCR. The U937-3xκB-LUCmonocyte cell line trans-
fected with a luciferase reporter gene was used to evaluate the anti-inflammatory properties
of Daiokanzoto. Daiokanzoto attenuated the P. gingivalis-mediated activation of the NF-κB
signaling pathway. It also reduced the secretion of pro-inflammatory cytokines (IL-6 and
CXCL8) by lipopolysaccharide-stimulated oral epithelial cells and gingival fibroblasts.
Lastly, Daiokanzoto, dose-dependently inhibited the catalytic activity of matrix metallopro-
teinases (-1 and -9). In conclusion, the present study provided evidence that Daiokanzoto
shows potential for treating and/or preventing periodontal disease. The ability of this Kampo
formulation to act on both bacterial pathogens and the host inflammatory response, the two
etiological components of periodontal disease, is of high therapeutic interest.
Introduction
Traditional Japanese herbal medicine, also called Kampo medicine, is practiced in Japan by
licensed medical professionals as well as by authorized Kampo practitioners to treat a wide
variety of diseases and to promote health [1, 2]. While only four Kampo formulations had been
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approved by 1967, there are now 148 different formulations recognized by the Japanese
national health insurance system [1, 2]. Kampo formulations, which are composed of mixtures
of crude extracts from the roots, bark, leaves, or rhizomes of a number of herbs, are manufac-
tured by Japanese pharmaceutical companies and are strictly controlled by government regula-
tions [1, 2]. Some of the phytochemicals in Kampo formulations likely act in synergy on
several therapeutic targets.
Periodontitis is a common inflammatory disorder that affects tooth-supporting tissues and
that may lead to tooth loss. Periodontitis has two major etiological components: (i) specific
Gram-negative anaerobic bacterial species, called periodontopathogens, that colonize subgingi-
val sites as biofilms [3], and (ii) the continuous host immune response to these periodonto-
pathogens that results in the production of high levels of inflammatory mediators and matrix
metalloproteinases (MMPs) that mediate the destruction of connective tissue and alveolar
bone [4, 5]. Very few studies of the beneficial effect of Kampo medicines on periodontal disease
have been published. Shosaikoto (TJ-9) and Orento (TJ-120) have been shown to suppress
lipopolysaccharide (LPS)-induced prostaglandin E2 production by human gingival fibroblasts
[6, 7], while Juzentaihoto (TJ-48) inhibits osteoclast differentiation in vitro and reduces alveo-
lar bone loss in a rat periodontitis model [8]. In a recent study, we showed that Rokumigan
(TJ-87) promotes wound healing in a gingival fibroblast model, attenuates pro-inflammatory
cytokine secretion by oral mucosal cells, and prevents biofilm formation by Fusobacterium
nucleatum [9], a bacterial species that plays an important role in bridging commensal Gram-
positive “early colonizers” and the periodontopathogenic Gram-negative “late colonizers” in
subgingival biofilm [10]. Lastly, we reported that Daiokanzoto (TJ-84) inhibits the growth and
adherence properties of Porphyromonas gingivalis [11], a key etiologic agent of chronic peri-
odontitis. More specifically, this bacterial expresses a broad array of virulence factors that allow
it to colonize subgingival sites, circumvent the immune system, and cause tissue destruction
[12]. Moreover, evidence has been brought that P. gingivalis can subvert the host immune
response to remodel a normally symbiotic bacterial community into a dysbiotic microflora
[13].
In this continuation of our ongoing research aimed at identifying the beneficial properties
of Daiokanzoto with a view to using it as a potential treatment for periodontal disease, we
investigated the impact of this Kampo formulation on virulence factor gene expression by P.
gingivalis, activation of the nuclear factor kappa B (NF-κB) signaling pathway and secretion of




Daiokanzoto was obtained from Tsumura Co. Ltd. (# D26692; Tokyo, Japan) as packaged pel-
lets. This Kampo is produced by combining crude extracts of Rhubarb rhizomes and Glycyr-
rhiza roots. A Daiokanzoto stock solution was prepared by adding 50 mg of pellets to 5 ml of
hot distilled water (80°C). The mixture was stirred for 1 h at 37°C and was then filter-sterilized
through a 0.22-μm pore size membrane. The filtrate was stored in the dark at 4°C for up to one
week.
Bacteria and growth conditions
The P. gingivalis ATCC 33277 reference strain was routinely grown in Todd-Hewitt broth
(Becton Dickinson, Mississauga, ON, Canada) supplemented with 0.001% hemin and 0.0001%
vitamin K (THB-HK) at 37°C in an anaerobic chamber (N2:H2:CO2 / 75:10:15).
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Virulence factor gene expression by P. gingivalis
The effect of Daiokanzoto on the expression of several P. gingivalis virulence factor genes
involved in host colonization (adhesins fimA and hagA) and tissue destruction (proteases rgpA
and rgpB) was investigated by reverse transcription (RT)-quantitative real-time polymerase
chain reaction (qPCR). The bacteria were grown to the mid-log phase (OD660 = 0.45). The
Daiokanzoto was added (100, 400, or 800 μg/ml final concentration), and the bacteria were
incubated at 37°C under anaerobic conditions for an additional 8 h. These concentrations were
below the minimal inhibitory concentration (MIC), which was evaluated at 1,000 μg/ml in a
previous study (11). Control cells were incubated in the absence of Daiokanzoto. The bacteria
were collected by centrifugation (7,000 x g for 5 min) and were treated with the RNAprotect
bacterial reagent (Qiagen Canada Inc., Montreal, QC, Canada). The bacterial cells were then
lysed, and their RNA was isolated and purified using RNeasy minikits (Qiagen Canada Inc.).
The purity of mRNA was evaluated using the ExperionTM system (Bio-Rad Laboratories, Mis-
sissauga, ON, Canada). Total cDNA was prepared from 1 μg of mRNA by RT-PCR using
iScriptTM Reverse Transcription Supermix (Bio-Rad Laboratories) according to the manufac-
turer’s instructions. The RT-PCR conditions were as follows: 5 min at 25°C, 30 min at 42°C,
and 5 min at 85°C. qPCR was used to quantify the levels of fimA, hagA, rgpA, and rgpB genes.
The 16S rRNA gene was used as a reference gene to normalize the results. The primers used for
the qPCR (Life Technologies Inc., Burlington, ON, Canada) have been described in a previous
study [14]. The PCR mixtures contained 5 μl of IQ SYBR Green Supermix (Bio-Rad Laborato-
ries), 4 μl of cDNA, 0.4 μl of gene-specific primer (10 mM), and 0.6 μl of RNase- and DNase-
free water. The samples were amplified using a Bio-Rad MyCyclerTM thermal cycler (Bio-Rad
Laboratories). The amplification conditions were as follows: 95°C for 5 min followed by 35
cycles at 95°C for 1 min, 52°C for 1 min, and 72°C for 30 s. Temperature curve analyses were
performed to validate the specificity of each primer pair. Assays were performed in triplicate
for a minimum of three independent experiments to ensure reproducibility. A representative
set of data is presented.
Activation of the NF-κB signaling pathway in monocytes
The human monoblastic leukemia cell line U937-3xκB-LUC, a subclone of the U937 cell line
stably transfected with a construct containing three NF-κB binding sites from the Ig κ light
chain promoter coupled with the firefly luciferase gene (3x-κB-luc), was kindly provided by R.
Blomhoff (University of Oslo, Norway) [15]. The cells were routinely grown at 37°C in a 5%
CO2 atmosphere in RPMI-1640 medium (Life Technologies Inc.) supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 μg/ml of penicillin-streptomycin, and 75 μg/ml
of hygromycin B (Sigma-Aldrich Canada Ltd., Oakville, ON, Canada). U937-3xκB-LUC
monocytes (2 x 106 cells/ml) were suspended in the supplemented RPMI-1640 culture medium
and were seeded (100 μl) in the wells of black-bottom, black-walled, 96-well microplates. Two-
fold serial dilutions of Daiokanzoto were then added to the wells (500 to 15.625 μg/ml). A pre-
liminary analysis showed that 500 μg/ml is the highest non-cytotoxic concentration of Daio-
kanzoto that can be used with this cell line (data not shown). An assay was also performed
using a commercial inhibitor (25 μM, BAY-11-7082; EMDMillipore, Billerica, MA, USA) of
the NF-κB signaling pathway. Following a 30-min incubation, P. gingivalis cells suspended in
the supplemented RPMI-1640 medium were added to the wells at an MOI of 100 to induce the
activation of the NF-κB signaling pathway. The plate was incubated at 37°C (5% CO2) for a
further 6 h. Luciferase substrate (100 μl) was added to the wells, and NF-κB activation was
monitored at room temperature using the Bright-Glo™ Luciferase Assay System (Promega,
Madison WI, USA). Luminescence was recorded using the luminometer option of a Synergy 2
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microplate reader (BioTek Instruments, Winooski, VT, USA) within 3 min of adding the
substrate.
Production of pro-inflammatory cytokines by lipopolysaccharide-
stimulated oral epithelial cells and gingival fibroblasts
The immortalized human oral epithelial cell line OBA-9 [16], which was kindly provided by
M. Mayer (University of São Paulo, Brazil), was cultured in keratinocyte serum-free medium
(K-SFM; Life Technologies Inc.) supplemented with growth factors (insulin, epidermal growth
factor, fibroblast growth factor) and 100 μg/ml of penicillin G-streptomycin. The HGF-1 pri-
mary human gingival fibroblast cell line (CRL-2014; American Type Culture Collection,
Manassas, VA, USA) was cultured in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 4 mM L-glutamine (HyClone Laboratories, Logan, UT, USA), 10% heat-inacti-
vated FBS, and 100 μg/ml of penicillin G-streptomycin. Both cell lines were incubated at 37°C
in a 5% CO2 atmosphere until they reached confluence. The cells were seeded in the wells of a
12-well microplate (1 ml/well, 1 x 106 cells/ml) and were incubated overnight at 37°C in a 5%
CO2 atmosphere to allow cell adhesion. Thereafter, the cells were pre-treated for 2 h with two-
fold serial dilutions of Daiokanzoto (100 to 25 μg/ml) prior to being stimulated with P. gingiva-
lis lipopolysaccharide (LPS, 1 μg/ml) for 24 h at 37°C in a 5% CO2 atmosphere. A preliminary
analysis showed that 100 μg/ml was the highest non-cytotoxic concentration of Daiokanzoto
for the two cell lines (data not shown). The supernatants were collected, centrifuged (500 x g
for 5 min at 4°C), and stored at –20°C until used to quantify interleukin-6 (IL-6) and interleu-
kin-8 (CXCL8) using commercial enzyme-linked immunosorbent assay (ELISA) kits (eBios-
cence Inc., San Diego, CA, USA) according to the manufacturer’s instructions.
Determination of MMP activity
Human recombinant MMP-9 (gelatinase B; Calbiochem, San Diego, CA, USA) was obtained
in the active form while human recombinant MMP-1 (collagenase; Calbiochem) was activated
at 37°C for 2 h in 10-fold TCNB buffer (50 mM TrisHCl, 10 mM CaCl2, 150 mMNaCl and
0.05% Brij35, pH 7.5) containing 1 mM p-aminophenylmercuric acetate. Active MMPs were
diluted to a final concentration of 100 ng/ml in TCNB buffer and increasing concentrations of
Daiokanzoto (0, 125, 250, and 500 μg/ml). Fluorogenic substrates (100 μg/ml; fluorescein-con-
jugated DQTM type I collagen and fluorescein-conjugated DQTM gelatin; Molecular Probes,
Eugene, OR, USA) were then added. The assay mixtures were incubated in the dark for 4 h at
room temperature for MMP-1 and 37°C for MMP-9. The fluorescence was measured using the
fluorometer option of a Synergy 2 microplate reader (BioTek Instruments) with the excitation
and emission wavelengths set at 490 nm and 520 nm, respectively.
Statistical analysis
Unless indicated otherwise, assays were performed in triplicate, and the means ± standard
deviations were calculated. Differences between the means were analyzed for statistical signifi-
cance using the Student’s t-test and were considered significant at p< 0.01.
Results
We first investigated the effect of Daiokanzoto on the expression of several virulence factor
genes by P. gingivalis. An early exponential growth phase culture of P. gingivalis was exposed to
Daiokanzoto at sub-MICs (100, 400 or 800 μg/ml) for 8 h under anaerobic conditions prior to
monitoring the expression of mRNA by RT-qPCR. Fig 1A shows the effects on two genes
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(fimA, hagA) coding for factors involved in bacterial colonization. A significant dose-depen-
dent decrease in the expression of both genes was observed. More specifically, the expression of
fimA and hagA decreased by 50.3% and 54.8%, respectively, in the presence of 800 μg/ml of
Daiokanzoto. The expression of rgpA and rgpB, two protease genes related to the inactivation
of host defense mechanisms, tissue destruction, and nutrient acquisition, also decreased by
74.9% and 67.6%, respectively, in the presence of 800 μg/ml of Daiokanzoto (Fig 1B).
To evaluate the anti-inflammatory properties of Daiokanzoto, the U937-3xκB-LUC cell line
transfected with a luciferase reporter gene was used to determine the effect of this Kampo for-
mulation on P. gingivalis-mediated activation of the NF-κB signaling pathway. Daiokanzoto
dose-dependently inhibited the activation of NF-κB induced by P. gingivalis at an MOI of 100
(Fig 2). The activation of NF-κB was reduced by 59.8% and 78.1%, respectively, in the presence
of 250 and 500 μg/ml of Daiokanzoto. The commercial inhibitor BAY-11-7082 (25 μM), which
was used as a positive control, completely prevented NF-κB activation.
The ability of Daiokanzoto to inhibit IL-6 and CXCL8 secretion by oral epithelial cells and
gingival fibroblasts was also tested. LPS stimulation of epithelial cells increased IL-6 secretion
45-fold and CXCL8 secretion 18-fold (Fig 3), while the stimulation of gingival fibroblasts with
LPS increased IL-6 secretion 67-fold and CXCL8 secretion 15-fold (Fig 4). Daiokanzoto signifi-
cantly decreased the secretion of IL-6 by both LPS-stimulated epithelial cells and fibroblasts
Fig 1. Effect of Daiokanzoto on the expression of fimA and hagA (Panel A) and rgpA and rgpBmRNA (Panel B) in P. gingivalis. Data are expressed
as means ± standard deviations. mRNA expression was normalized to 16S rRNA. *, significantly different (P < 0.01) compared to an untreated control.
doi:10.1371/journal.pone.0148860.g001
Fig 2. Effect of Daiokanzoto on P. gingivalis-induced activation of the NF-κB signaling pathway in monocytes. Data are expressed as
means ± standard deviations. *, Significant inhibition at p < 0.01 using a Student’s t-test.
doi:10.1371/journal.pone.0148860.g002
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(Figs 3 and 4). Daiokanzoto (100 μg/ml) decreased IL-6 secretion by fibroblasts and epithelial
cells by 73.3% and 71%, respectively. While it had no effect on the secretion of CXCL8 by gingi-
val fibroblasts, Daiokanzoto significantly and dose-dependently decreased the secretion of
CXCL8 by epithelial cells (Fig 3). At 100 μg/ml, it inhibited CXCL8 secretion by 53.5%.
Lastly, since tissue destruction associated with periodontitis is mostly mediated by MMPs,
we evaluated the effect of Daiokanzoto on the catalytic activity of MMP-1 and MMP-9, which
Fig 3. Effect of Daiokanzoto on IL-6 (Panel A) and CXCL8 (Panel B) secretion by LPS-stimulated human oral epithelial cells (OBA-9).Data are
expressed as means ± standard deviations. *, Significant inhibition at p < 0.01 using a Student’s t-test.
doi:10.1371/journal.pone.0148860.g003
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are secreted by several human cell types. Daiokanzoto at 500 μg/ml inhibited type I collagen
degradation by MMP-1 by 72% (Table 1). Similarly, Daiokanzoto (500 μg/ml) caused inhibi-
tion of MMP-9-mediated gelatin degradation (83.1%) (Table 1).
Discussion
Approximately 5–15% of the general population is affected by severe forms of periodontal dis-
ease [17] that, if left untreated, may result in tooth loss and systemic complications such as car-
diovascular diseases, preterm delivery, rheumatoid arthritis, and respiratory infections [18].
Fig 4. Effect of Daiokanzoto on IL-6 (Panel A) and CXCL8 (Panel B) secretion by LPS-stimulated human gingival fibroblasts (HGF-1). Data are
expressed as means ± standard deviations. *, Significant inhibition at p < 0.01 using a Student’s t-test.
doi:10.1371/journal.pone.0148860.g004
Anti-Bacterial and Anti-Inflammatory Properties of Daiokanzoto
PLOS ONE | DOI:10.1371/journal.pone.0148860 February 9, 2016 8 / 12
The conventional treatment for periodontitis involves the mechanical removal of the subgingi-
val biofilm and tartar that induce the host immune-destructive response. While this procedure
is effective in managing the majority of periodontitis patients, conventional therapy does not
always achieve the desired clinical outcome. For instance, controlling periodontitis in high-risk
individuals (smokers, diabetics or individuals possessing genetic predisposition) or individuals
who do not respond to conventional therapy may require adjunctive treatments [19].
Recent evidence has suggested that Kampo formulations may possess potentially valuable
properties for treating oral diseases. More specifically, antibacterial, anti-inflammatory, and
wound healing activities have been associated with some Kampo formulations [6–9, 11]. In a
recent study, we showed that Daiokanzoto (TJ-84) exerts antibacterial activity against P. gingi-
valis and attenuates some the virulence properties of this bacterium [11]. The goal of the pres-
ent study was to provide additional evidence of the potential of Daiokanzoto for treating
periodontal disease.
Given the critical role of P. gingivalis in chronic periodontitis [12], compounds that attenu-
ate the virulence properties of this bacterium are of great interest. We showed that Daiokanzoto
reduces the expression of fimA and hagA, which are involved in host colonization by P. gingiva-
lis [20]. Interestingly, in a previous study, Daiokanzoto was shown to reduce the adherence of
P. gingivalis to gingival epithelial cells [11], suggesting that this Kampo formulation could
potentially be used for an anti-infective strategy based on preventing the adherence of patho-
gens to mucosal surfaces. The expression of rgpA and rgpB, two protease genes that are associ-
ated with the inactivation of host defense mechanisms, tissue destruction, and nutrient
acquisition [21] was also down-regulated when P. gingivalis was incubated with Daiokanzoto
at sub-MICs. Interestingly, we previously reported the ability of Daiokanzoto to inhibit the gin-
gipain-mediated gelatin degradation by P. gingivalis [11].
The transcription factor NF-κB is activated by a wide variety of stimuli, including bacterial
pathogens, and has many target genes, including genes encoding cytokines, adhesion mole-
cules, and MMPs [22]. Therapeutic approaches that inhibit inflammatory mediator production
by host cells represent an interesting alternative for controlling inflammatory diseases such as
periodontal diseases [23]. We showed that Daiokanzoto inhibits NF-κB activation by P. gingi-
valis. Daiokanzoto is a mixture of crude extracts of Rhubarb rhizomes and Glycyrrhiza roots.
Interestingly, some of the active constituents of Glycyrrhiza spp., including flavanones, chal-
cones, isoflavans, flavones, and isoflavones, have been reported to inhibit NF-κB activation in
various cell types [24].
Fibroblasts and epithelial cells are major constituents of gingival tissues and act as a physical
barrier to prevent invasion by periodontopathogens [25]. In response to stimulation by
periodontopathogens and their virulence factors, these cells secrete pro-inflammatory cyto-
kines such as IL-6 and CXCL8 [26, 27]. The periodontal tissues and gingival crevicular fluid of
Table 1. Effect of Daiokanzoto on the activity of MMP-1 andMMP-9.
Concentration (μg/ml) Relative activity (%) 1
MMP-1 MMP-9
0 100 ± 8.4 100 ± 9.6
125 79.8 ± 17.1 85.3 ± 8.1
250 65.2 ± 10.6 2 54.7 ± 12.4 2
500 28.0 ± 12.9 2 16.9 ± 6.6 2
1 Data are expressed as means ± standard deviations.
2 Signiﬁcant inhibition at p < 0.01 using a Student’s t-test.
doi:10.1371/journal.pone.0148860.t001
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periodontitis patients contain high levels of inflammatory mediators, and their etiological cor-
relation with periodontitis has been clearly demonstrated [28]. It is thus logical to investigate
therapeutic approaches that modulate the host inflammatory response in order to manage the
progression of chronic periodontitis. In the present study, we showed that Daiokanzoto inhib-
its LPS-induced IL-6 secretion by both gingival fibroblasts and epithelial cells. The expression
of IL-6 has been shown to be higher in periodontal inflammation sites and to be closely related
to the clinical severity of periodontitis [29]. In addition, IL-6 levels are also higher in the dis-
eased gingiva of patients with periodontitis than in the gingiva of periodontally healthy subjects
[30]. IL-6 is a multifunctional cytokine that can induce osteoclast formation and promote bone
resorption [31, 32]. While this occurs naturally as part of normal bone remodeling, excess IL-6
production, as during periodontitis, leads to the destruction of alveolar bone. By attenuating
the secretion of IL-6, Daiokanzoto may contribute to reducing bone resorption. Oral epithelial
cells are known to secrete chemokines, including CXCL8, which are chemoattractants for poly-
morphonuclear leukocytes and macrophages. Interestingly, increased levels of CXCL8 are
found in the gingival crevicular fluid of inflamed periodontal sites compared with healthy sites
[33]. Moreover, periodontal therapy reduces immune cell numbers, and the levels of CXCL8 in
gingival crevicular fluid [34]. Given the above, the ability of Daiokanzoto to inhibit CXCL8
secretion by epithelial cells may attenuate periodontal inflammation. Two other Kampo formu-
lations, Shosaikoto (TJ-9) and Orento (TJ-120), have also been reported to possess anti-inflam-
matory activity through their ability to suppress LPS-induced prostaglandin E2 (PGE2)
production by gingival fibroblasts [6, 7].
MMPs are proteolytic enzymes released by major cell types in the periodontium, including
fibroblasts, neutrophils, and macrophages [5]. Since these enzymes can degrade most compo-
nents of the extracellular matrix (ECM), high levels of MMPs in active periodontal sites lead to
the destruction of periodontal tissues by the degradation of periodontal ligaments, the loss of
gingival collagen, and the resorption of alveolar bone [5]. High levels of active MMP-9 in gingi-
val crevicular fluid have been associated with periodontal tissue destruction [35]. In addition,
periodontitis-affected gingival tissue express high levels of MMP-1 mRNA [36]. We showed
that Daiokanzoto inhibits the catalytic activity of both MMP-1 and MMP-9 and may thus con-
tribute to reducing host cell damage, including bone resorption.
Yoshida et al. [37] recently showed that Daiokanzoto can attenuate 5-fluorouracil-induced
cell death by inhibiting the production of mitochondrial reactive oxygen species. This led to the
suggestion that Daiokanzoto could be used to treat oral mucositis in patients receiving multicycle
chemotherapy. The present study provided evidence that Daiokanzoto could potentially be used
to treat periodontal disease, another major oral disorder. Clinical trials are now required to assess
the potential oral health benefits Daiokanzoto. In this regard, bioactive molecules could be
applied locally to diseased periodontal sites by irrigation or by the insertion of resorbable fibers
to attenuate the virulence properties of P. gingivalis as well as the inflammation process.
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